Participants should be aware of the following financial/non-financial relationships:
Alan Pollack, MD, PhD: Disclosure information not submitted.
Learning Objectives:
To understand the level I evidence supporting the benefit of adding androgen deprivation therapy to standard prostate bed radiotherapy.
To appreciate the level I evidence related to the value of pelvic lymph node treatment in the context of patient and treatment factors, such as pelvic lymph node risk
To recognize the patient risk and imaging factors associated with patient selection for salvage radiotherapy treatment intensification with androgen deprivation therapy and pelvic lymph node treatment
